secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001689548-25-000086
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Breakthrough Therapy Designation for relutrigine in SCN2A/SCN8A DEEs
-------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for relutrigine in pediatric SCN2A and SCN8A DEEs.
- BTD supported by positive data from EMBOLD study cohort 1 and 11-month open-label extension data.
- Company initiated EMERALD study evaluating relutrigine across all DEEs.
- Company entered quiet period ahead of RADIANT Phase 2 topline results expected by mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000086/0001689548-25-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000086/prax-20250717.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer